Blood test to predict response to anti-TNF treatment for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study is testing whether a simple blood test can help predict how well patients respond to anti-TNF alpha treatments (like Humira or Enbrel) for rheumatoid arthritis. If successful, this could help doctors choose the right medication sooner, saving you time and improving your quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a confirmed diagnosis of rheumatoid arthritis.
- Your disease is active — meaning you have significant joint pain, swelling, or stiffness.
- You have never received biological medications (like Humira or Enbrel) or targeted synthetic DMARDs (like JAK inhibitors) for your RA.
- Your doctor has decided to start treatment with an anti-TNF alpha medication.
- You cannot have a history of cancer or be currently treating cancer.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a new blood test that might help doctors diagnose rheumatoid arthritis, especially for people who don't have the usual markers in their blood. It could help more people get the right diagnosis earlier.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.